PIRS - Pieris Pharmaceuticals Inc Net earnings per share (EPS TTM)
The development of the Anticalin platform to combat cancer and respiratory pathologies is driving the company, as demonstrated by the annual net income per share trend on the GURU.Markets terminal chart, where -5.47 captures the value of this parameter. The scientific authority of Pieris Pharmaceuticals (PIRS) is based on the creation of unique protein therapies, however, sharp workforce reductions and stagnant testing have limited the business's scalability.
Comprehensive metric breakdowns and analytics for Pieris (PIRS)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Pieris Pharmaceuticals|PIRS - Long-Term Liabilities to Equity|Short-Term Debt to Capital pieris.com|PIRS - Company Total Debt Obligations|Debts to Book Capitalization Pieris Pharmaceuticals, Inc.|PIRS - Long-Term Debt|Company Short-Term Debt Pieris Pharmaceuticals|Quick Ratio pieris.com
- net income and valuation multiples indicators:
PIRS - Net Financial Result|Expected Profit Pieris Pharmaceuticals|PIRS - Business Payback Period|Projected Price to Earnings Pieris|PIRS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals Inc|PIRS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Pieris Pharmaceuticals|PIRS - Earnings per share for the trailing year|Quarterly EPS earnings growth pieris.com|PIRS - Earnings growth in current year|Net earnings per share growth forecast for next year Pieris Pharmaceuticals
- revenue and sales proceeds data:
Fundamental company analysis:Pieris Pharma (PIRS)
Pieris Pharmaceuticals focuses on high-cost R&D in oncology and respiratory pathologies. The EPS TTM metric measures the final net income allocated per common share over a year. Negative values here reflect investments in science, while their reduction signals an approach toward monetization. Analyzing the trend allows for an assessment of capital management efficiency. The 12-month earnings per share history clearly demonstrates the pace of the business's financial transformation.
Main competitors
Haleon - Net earnings per share (EPS TTM)|Kenvue - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Corp - Earnings per share for the trailing year|LGND (Ligand Pharmaceuticals Incorporated) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months amneal.com AMRX|Earnings per share for the last twelve months Perrigo (PRGO)|ALVO (Alvotech SA) - Earnings per share for the trailing year|Earnings per share for the last twelve months Liquidia Technologies LQDA|Net earnings per share for the trailing year Galapagos Genomics|ANIP - Earnings per share for the last twelve months|MNKD - Net earnings per share (EPS TTM)|Amphastar Pharmaceuticals (AMPH) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Pacira BioSciences, Inc.|Net earnings per share for the last 12 months SPRY|TBPH: Earnings per share for the trailing year|Earnings per share for the last twelve months aquestive.com (AQST)|Net earnings per share (EPS TTM) scPharmaceuticals, Inc. (SCPH)|Earnings per share for the last twelve months tectonictx.com TECX|Earnings per share for the trailing year TNXP|SXTC - Earnings per share for the last twelve months|Net earnings per share for the last four quarters eupraxiapharma.com EPRX|BHST: Net earnings per share (EPS TTM)|EXOZ - Net earnings per share for the last four quarters|ORMP (oramed.com) - Net earnings per share (EPS TTM)|enterabio.com (ENTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) HYFT|ABVC (ABVC BioPharma Inc) - Earnings per share for the trailing year|Cumberland Pharmaceuticals - Net earnings per share for the last 12 months|quantumbiopharma.com (QNTM) - Net earnings per one share for the last twelve months|FibroGen Inc - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TELO (Telomir Pharmaceuticals Inc)|RANI (Rani Therapeutics Holdings, Inc.) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Synergy CHC Corporation|Earnings per share for the last twelve months Rallybio Corp|Lexaria Bioscience (LEXX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pulmatrix, Inc. (PULM)|Net earnings per share for the last four quarters Pheton|Earnings per share for the last twelve months Aptorum Group Limited APM|LYRA - Net earnings per share for the last 12 months|IBO: Net earnings per share for the last 12 months|TNFA - Net earnings per share (EPS TTM)|cbdMD Corp (YCBD) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months PRFX (PainReform Limited)|CYTO (Altamira Therapeutics Ltd.) - Net earnings per share (EPS TTM)|Lipella (LIPO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) OPTN|PROC (procapsgroup.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Petros Pharmaceuticals, Inc. PTPI|Qilian International Holding - Earnings per share for the last twelve months|SLRN - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TFFP
